© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341
Standard cell lines used in cytotoxicity assays often lack clinically relevant tumour surface antigens and are clonal in nature, therefore losing the intratumor and inter-patient heterogeneity observed in the clinic, which is known to influence ADC response. Conversely, in vivo patient-derived models, such as PDX, represent a more relevant approach for preclinical ADC testing but may be difficult to expand and maintain in live passage for large scale studies.